Literature DB >> 24782508

TBLR1 fuses to retinoid acid receptor α in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.

Yirui Chen1, Shouyun Li1, Chunlin Zhou2, Chengwen Li3, Kun Ru3, Qing Rao1, Haiyan Xing1, Zheng Tian1, Kejing Tang1, Yingchang Mi2, Baohong Wang4, Min Wang1, Jianxiang Wang5.   

Abstract

The majority of acute promyelocytic leukemia (APL) cases are characterized by the PML-RARα fusion gene. Although the PML-RARα fusion gene can be detected in >98% of APL cases, RARα is also found to be fused with other partner genes, which are also related to all-trans retinoic acid (ATRA)-dependent transcriptional activity and cell differentiation. In this study, we identified a novel RARα fusion gene, TBLR1-RARα (GenBank KF589333), in a rare case of APL with a t(3;17)(q26;q21),t(7;17)(q11.2;q21) complex chromosomal rearrangement. To our knowledge, TBLR1-RARα is the 10th RARα chimeric gene that has been reported up to now. TBLR1-RARα contained the B-F domains of RARα and exhibited a distinct subcellular localization. It could form homodimers and also heterodimers with retinoid X receptor α. As a result, TBLR1-RARα exhibited diminished transcriptional activity by recruitment of more transcriptional corepressors compared with RARα. In the presence of pharmacologic doses of ATRA, TBLR1-RARα could be degraded, and its homodimerization was abrogated. Moreover, when treated with ATRA, TBLR1-RARα could mediate the dissociation and degradation of transcriptional corepressors, consequent transactivation of RARα target genes, and cell differentiation induction in a dose- and time-dependent manner.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24782508     DOI: 10.1182/blood-2013-10-528596

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.

Authors:  Erin M Swaney; Anuja Chattopadhyay; Irina Abecassis; Elizabeth A Rush; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2016-01-12

Review 2.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Authors:  Miguel A Sanz; Pierre Fenaux; Martin S Tallman; Elihu H Estey; Bob Löwenberg; Tomoki Naoe; Eva Lengfelder; Hartmut Döhner; Alan K Burnett; Sai-Juan Chen; Vikram Mathews; Harry Iland; Eduardo Rego; Hagop Kantarjian; Lionel Adès; Giuseppe Avvisati; Pau Montesinos; Uwe Platzbecker; Farhad Ravandi; Nigel H Russell; Francesco Lo-Coco
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

Review 3.  TBL1XR1 in physiological and pathological states.

Authors:  Jian Yi Li; Garrett Daniels; Jing Wang; Xinmin Zhang
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

4.  IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.

Authors:  Samir Mazharuddin; Anuja Chattopadhyay; Moshe Y Levy; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2018-01-19

5.  NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFκB and JNK.

Authors:  Anuja Chattopadhyay; Irina Abecassis; Robert L Redner
Journal:  Leuk Lymphoma       Date:  2015-10-05

6.  Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.

Authors:  Qian-Qian Wang; Liaqat Hussain; Pei-Han Yu; Chang Yang; Chen-Ying Zhu; Ya-Fang Ma; Si-Chun Wang; Tao Yang; Yuan-Yuan Kang; Wen-Juan Yu; Yasen Maimaitiyiming; Hua Naranmandura
Journal:  Acta Pharmacol Sin       Date:  2022-10-10       Impact factor: 7.169

Review 7.  Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics.

Authors:  Li Jiang; Rong Dong; Meidan Ying; Qiaojun He; Ji Cao; Bo Yang
Journal:  Br J Pharmacol       Date:  2018-11-08       Impact factor: 8.739

8.  Pathways of retinoid synthesis in mouse macrophages and bone marrow cells.

Authors:  Haixia Niu; Gayla Hadwiger; Hideji Fujiwara; John S Welch
Journal:  J Leukoc Biol       Date:  2016-01-14       Impact factor: 4.962

Review 9.  Current views on the genetic landscape and management of variant acute promyelocytic leukemia.

Authors:  Xiang Zhang; Jiewen Sun; Wenjuan Yu; Jie Jin
Journal:  Biomark Res       Date:  2021-05-06

10.  A novel fusion protein TBLR1-RARα acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies.

Authors:  Shouyun Li; Xue Yang; Shuang Liu; Yirui Chen; Haiyan Xing; Kejing Tang; Zheng Tian; Yingxi Xu; Qing Rao; Min Wang; Jianxiang Wang
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.